Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients
1. ATAI and Beckley reported promising data on BPL-003 for TRD. 2. Significant improvements in MADRS scores were observed post-dosing. 3. BPL-003 was well-tolerated, with mild to moderate side effects only. 4. FDA engagement for Phase 3 trials expected in early 2026. 5. Analyst maintains Buy rating with a $15 price target.